2.2 Study population
Consecutive patients who were admitted between March 2019 and March 2020 and were treated with a combined antithrombotic therapy enrolled in this study. Inclusion criteria were that the combined therapy existed of one OAC (VKA and/or DOAC) combined with one (double antithrombotic therapy, DAT) or two PAI’s (triple antithrombotic therapy, TAT).
Exclusion criteria were if the combination existed of only PAI’s (dual antiplatelet therapy (DAPT)) without OAC. Exclusion also occurred if admission was less than 24 hours.